HRT Is Not the Only Option: A Functional Medicine Approach to Perimenopause and Menopause

non-hrt-menopause-alternatives-functional-medicine-utah-wendy-edwards-aniron-functional-medicine-integrative-psychiatry

Non-HRT menopause alternatives in Utah are more effective and more evidence-informed than most women realize.Hormone replacement therapy works well for many women. However, it is not appropriate for everyone. Women with a history of hormone-sensitive cancers, blood clots, deep vein thrombosis, endometriosis, or certain cardiovascular conditions often cannot use HRT safely. Others simply choose not to. For these women, the answer is not to go without support.

At Aniron Functional Medicine and Integrative Psychiatry, Wendy Edwards, MSN, APRN, FNP-BC, PMHNP-BC takes a root-cause approach to menopause and perimenopause that goes well beyond hormones. She addresses the biological systems that drive symptoms, liver detoxification, insulin resistance, gut health, cortisol regulation, thyroid function, inflammation, and nutritional status, and uses evidence-informed supplements as part of a comprehensive, personalized plan. This article explains what that approach looks like. Call Aniron Functional Medicine and Integrative Psychiatry today at (801) 889-2995 to schedule your consultation in Lehi or Bountiful.


Why HRT Is Not an Option for Every Woman

For some women, HRT carries real clinical risks. Women with a personal history of estrogen-receptor-positive breast cancer, endometrial cancer, or ovarian cancer often receive guidance to avoid systemic estrogen. A narrative review published in PMC confirmed that HRT remains contraindicated in women with previous hormone-dependent cancer, and that these women require personalized non-hormonal strategies for managing menopausal symptoms.

Additionally, women with active or prior deep vein thrombosis, pulmonary embolism, or thrombophilia face elevated clotting risk with oral estrogen therapy. Similarly, women with severe liver disease, unexplained vaginal bleeding, or certain cardiovascular conditions require careful individual evaluation before any hormone therapy. Furthermore, some women simply do not tolerate HRT well. They experience side effects and prefer to explore other paths. In all of these cases, consequently, a root-cause functional medicine approach offers a meaningful and evidence-informed alternative.

The Root-Cause Approach: What Drives Menopause Symptoms Beyond Hormones

Most conventional care treats menopause symptoms individually. For instance, a hot flash gets one prescription. Insomnia gets another. Mood symptoms get a third. However, a functional medicine approach asks a different question: what biological systems are out of balance and why are symptoms this severe? In fact, the answers often point to several interconnected root causes. As a result, addressing them produces broader and more lasting relief than symptom-by-symptom management alone.

Optimizing Liver Function for Hormone Metabolism

The liver plays a central role in hormone health. It processes and eliminates used estrogen through phase I and phase II detoxification pathways. When liver function is sluggish, due to poor diet, toxin exposure, alcohol, or gut dysfunction, used estrogen recirculates rather than clearing properly. This drives estrogen dominance, worsens hot flashes and mood symptoms, and increases long-term risk.

Cruciferous vegetables contain indole-3-carbinol, which converts to diindolylmethane (DIM) in the body. A review published in PubMed confirmed that DIM supports phase I liver detoxification and shifts estrogen metabolism toward less stimulating metabolites, specifically 2-hydroxyestrone, which carries a lower cancer risk profile. Additionally, research confirmed that compounds in cruciferous vegetables support both phases I and II of liver detoxification, helping the body eliminate excess hormones and toxins more efficiently. Therefore, Wendy evaluates liver function and detoxification capacity as part of her comprehensive menopause assessment. Dietary strategies, targeted supplements, and reduction of toxin exposure all support liver health as a foundation of hormonal balance.

Reducing Insulin Resistance

Insulin resistance accelerates during menopause. Estrogen helps regulate insulin sensitivity. As estrogen declines, blood sugar dysregulation worsens. Abdominal weight gain increases. Inflammation rises. Hot flashes become more frequent and more severe. Insulin resistance and menopause symptoms feed each other in a self-reinforcing cycle.

Addressing insulin resistance through a low-glycemic, anti-inflammatory diet, regular strength training, targeted supplementation, and metabolic lab monitoring breaks that cycle. Fasting insulin, hemoglobin A1c, and inflammatory markers give a clear picture of metabolic health that many standard menopause evaluations never assess.

Improving Sleep and Cortisol Regulation

Poor sleep and elevated cortisol form one of the most disruptive cycles in menopause. Declining estrogen and progesterone disrupt sleep architecture directly. Night sweats interrupt deep sleep. Poor sleep elevates cortisol the following day. Elevated cortisol then worsens hot flashes, drives abdominal weight gain, suppresses immune function, and disrupts sleep again the next night.

Phosphatidylserine directly addresses the cortisol side of this cycle. A randomized, placebo-controlled study published in PMC found that phosphatidylserine supplementation normalized HPA axis reactivity and significantly reduced cortisol responses to stress in chronically stressed subjects. Glycine addresses the sleep side. Research published in PMC found that glycine promotes deeper sleep by working through NMDA receptors in the suprachiasmatic nucleus, the brain’s circadian clock, and reduces core body temperature to support sleep onset. A study published in PubMed also found that a combination including glycine improved sleep disturbance and irritability specifically in peri and postmenopausal women.

Relora, a proprietary blend of Magnolia officinalis and Phellodendron amurense, also supports cortisol regulation. A randomized, double-blind, placebo-controlled trial published in the Journal of the International Society of Sports Nutrition found that Relora reduced salivary cortisol by 18% and significantly improved mood, sleep, and stress-related eating in moderately stressed adults.

Reducing Chronic Inflammation

Chronic inflammation worsens every menopause symptom. It drives hot flash severity, disrupts mood, accelerates bone loss, raises cardiovascular risk, and impairs cognitive function. As estrogen declines, its natural anti-inflammatory effects also decline. The body becomes more vulnerable to inflammatory triggers from diet, gut dysfunction, stress, and environmental exposures.

An anti-inflammatory dietary approach, rich in vegetables, healthy fats, fiber, and phytonutrient-dense foods, forms the foundation of inflammation management at Aniron Functional Medicine and Integrative Psychiatry. Specialty lab testing including high-sensitivity CRP, homocysteine, and inflammatory cytokines identifies the degree of systemic inflammation driving each patient’s symptoms. Targeted supplementation then addresses inflammation at its source.

Improving Gut Health

The gut and hormones are deeply interconnected. A specialized collection of gut bacteria called the estrobolome regulates how the body processes and eliminates used estrogen. When gut dysbiosis disrupts the estrobolome, estrogen recirculates rather than clearing, worsening symptoms and increasing long-term risk. Additionally, the gut produces a significant portion of the body’s serotonin. Poor gut health drives poor mood, disrupted sleep, and increased anxiety, all common complaints during the menopause transition.

Wendy uses the GI Map and specialty stool testing to evaluate gut health directly. Protocols to restore the gut microbiome, repair the gut lining, and reduce intestinal permeability form an important layer of the overall non-HRT menopause management plan.

Improving Nutritional Status

Nutritional deficiencies directly worsen menopause symptoms. Many women enter perimenopause already depleted in key nutrients, magnesium, vitamin D, B vitamins, and omega-3 fatty acids, without knowing it. Standard blood panels rarely screen for these deficiencies. Comprehensive micronutrient testing at Aniron Functional Medicine and Integrative Psychiatry identifies specific gaps and guides targeted supplementation.

Optimizing Thyroid Function

Thyroid dysfunction and menopause produce almost identical symptoms. Fatigue, weight gain, brain fog, depression, cold intolerance, hair thinning, and mood changes all appear in both conditions. Many women in perimenopause have undiagnosed subclinical thyroid dysfunction driving or compounding their symptoms. Standard TSH testing misses this regularly.

Wendy measures free T3, free T4, reverse T3, and thyroid antibodies as part of her comprehensive evaluation. When thyroid dysfunction is identified and addressed, many women experience significant relief from symptoms they had attributed entirely to menopause.

Key Supplements in a Non-HRT Approach to Menopause


Magnesium

Magnesium supports sleep, nervous system regulation, bone health, mood, and cortisol balance, all areas of critical concern during menopause. A 2024 study published in the Journal of Affective Disorders found that magnesium deficiency scores significantly correlated with poor sleep quality in adults. A pilot phase II trial published in Support Care Cancer found that magnesium supplements reduced menopausal hot flash frequency and severity specifically in breast cancer patients, exactly the population who cannot use HRT. A 2023 systematic review and meta-analysis confirmed that magnesium supplementation helped improve mild to moderate depressive symptoms, relevant given that depression affects over 40% of perimenopausal women.

Magnesium glycinate is the preferred form at Aniron Functional Medicine and Integrative Psychiatry. It is gentle on the gut, well absorbed, and supports both sleep and nervous system calm.

Omega-3 Fatty Acids — EPA and DHA

EPA and DHA reduce inflammation, support brain health, protect cardiovascular function, and may reduce the frequency and severity of hot flashes and mood symptoms during menopause. A systematic review published in PMC analyzing randomized controlled trials found that omega-3 polyunsaturated fatty acid supplementation showed beneficial effects on vasomotor symptoms, sleep quality, and depression in postmenopausal women. A preliminary open trial published in PubMed found that 2 grams of EPA and DHA daily for 8 weeks reduced both depression scores and hot flash frequency in women during the menopausal transition. A 2025 narrative review published in a peer-reviewed journal found that increasing EPA and DHA intake is associated with improved brain function during the menopausal transition, with promising evidence for mood, cognition, and anxiety.

It is important to note that omega-3 evidence for menopause symptoms shows promise but is not yet conclusive across all studies. High-quality, third-party-tested fish oil remains a well-tolerated, low-risk intervention with cardiovascular and cognitive benefits that extend well beyond symptom relief.

Vitamin D3 and K2

Declining estrogen accelerates bone loss. Vitamin D3 drives calcium absorption, supports bone mineralization, regulates immune function, and supports mood. K2 activates the vitamin-K-dependent proteins that direct calcium into bone and away from arteries. These two nutrients work synergistically. A comprehensive review published in Nutrients found that combined D3 and K2 supplementation supports bone metabolism and may help preserve bone mineral density in postmenopausal women, particularly those with low dietary K or borderline vitamin D status. A systematic review and meta-analysis published in Frontiers in Public Health found that vitamin K2 supplementation was efficacious in the prevention and treatment of postmenopausal osteoporosis.

Women taking warfarin must discuss vitamin K2 with their provider before supplementing, as it affects clotting pathways. Wendy evaluates vitamin D levels through lab testing before supplementing and monitors levels over time.

Methylated B Complex

B vitamins support methylation, mood, energy, and neurotransmitter production, all of which decline during the menopause transition. Many women carry MTHFR gene variants that impair their ability to convert synthetic folic acid into the active methylfolate form the brain can use. As a result, standard B vitamins provide less benefit than methylated forms.

A methylated B complex, including methylcobalamin (B12), methylfolate (B9), and active forms of B6 supports serotonin and dopamine synthesis, reduces homocysteine, and supports liver phase II detoxification. Elevated homocysteine, common in women with MTHFR variants and B vitamin deficiency raises cardiovascular risk during menopause. Wendy evaluates methylation status, MTHFR variants, and homocysteine levels as part of her comprehensive assessment and uses methylated forms when indicated.

Glycine

Glycine is an inhibitory amino acid that supports sleep onset, nervous system calm, and core body temperature regulation. Research published in PMC found that glycine promotes deeper sleep through NMDA receptors in the suprachiasmatic nucleus and reduces core body temperature to support sleep onset. A study published in PubMed found that glycine combined with other calming nutrients improved sleep disturbance and irritability specifically in peri and postmenopausal women. Glycine works through temperature regulation and circadian timing rather than sedation, making it a well-tolerated option for women who want sleep support without pharmacological side effects.

Relora

Relora is a proprietary blend of Magnolia officinalis and Phellodendron amurense bark extracts. It supports cortisol regulation, reduces stress-related eating, and promotes calm without sedation. A randomized, double-blind, placebo-controlled trial published in the Journal of the International Society of Sports Nutrition found that Relora reduced salivary cortisol by 18% and significantly improved mood, sleep quality, and stress-related eating behaviors in moderately stressed adults over four weeks. For perimenopausal and menopausal women whose symptoms are driven significantly by elevated cortisol and HPA axis dysregulation, Relora offers a well-tolerated, evidence-informed option.

Phosphatidylserine

Phosphatidylserine is a phospholipid found in high concentrations in brain cell membranes. It blunts cortisol secretion particularly the elevated evening cortisol that disrupts sleep onset and drives the anxiety and hyperarousal many women experience during menopause. A randomized, placebo-controlled study published in PMC found that phosphatidylserine and phosphatidic acid supplementation normalized HPA axis reactivity and significantly reduced cortisol responses to stress in chronically stressed subjects. Research published in Sports Medicine confirmed that 600 mg of phosphatidylserine daily reduced cortisol levels by 20% in response to stress. It is particularly useful for women with stress-related insomnia, racing thoughts at bedtime, and fatigue-despite-tiredness patterns.

FDA-Approved Non-Hormonal Prescription Medications for Hot Flashes

A significant development in menopause care has arrived for women who cannot use HRT. Two FDA-approved non-hormonal prescription medications now specifically target the brain pathway responsible for hot flashes and night sweats. Both represent a meaningful advancement for women with cancer, blood clots, DVT, endometriosis, or other contraindications to hormone therapy.

Veozah (Fezolinetant)

Veozah is the brand name for fezolinetant. The FDA approved Veozah on May 12, 2023, making it the first-in-class NK3 receptor antagonist approved specifically for moderate to severe vasomotor symptoms due to menopause. Falling estrogen levels cause KNDy neurons in the hypothalamus to overstimulate the body’s heat-sensing pathway. This overactivation produces hot flashes. Fezolinetant blocks the NK3 receptor on these neurons directly, calming that overactivation at its neurological source.

Three Phase III clinical trials, SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 demonstrated that fezolinetant significantly reduced both the frequency and severity of hot flashes compared to placebo. Veozah is taken as a 45 mg oral tablet once daily. It contains no estrogen or progesterone. This makes it a meaningful option for women with hormone-sensitive cancers, DVT, or other HRT contraindications.

However, Veozah carries important safety considerations. In 2024 the FDA added a boxed warning after rare but serious cases of liver injury were identified. Women with liver disease or elevated liver enzymes should not take Veozah. Baseline and follow-up liver function testing is required. At Aniron Functional Medicine and Integrative Psychiatry, liver health is evaluated before prescribing and monitored closely throughout treatment.

Lynkuet (Elinzanetant)

Lynkuet is the brand name for elinzanetant. The FDA approved Lynkuet on October 24, 2025, making it the first and only dual neurokinin receptor antagonist, blocking both NK1 and NK3 receptors, approved for moderate to severe hot flashes due to menopause. This dual mechanism sets it apart from Veozah. By blocking both NK1 and NK3 receptors, Lynkuet addresses thermoregulation and also targets Substance P signaling, which influences mood and sleep quality. This makes it potentially more comprehensive than fezolinetant for women who experience significant sleep disruption alongside hot flashes.

Three Phase III clinical trials, OASIS 1, OASIS 2, and OASIS 3, evaluated Lynkuet in over 1,400 women. Results showed that Lynkuet significantly reduced the frequency and severity of moderate to severe hot flashes at both week 4 and week 12. A study published in JAMA Internal Medicine found a 74% reduction in daily moderate-to-severe hot flashes in women who took elinzanetant over 12 weeks, compared to 47% in those who took placebo. Lynkuet is taken as a 60 mg soft gel capsule once daily at bedtime. It is non-hormonal.

Important safety considerations include potential central nervous system effects, daytime impairment, elevated liver enzyme values, and a risk of seizures in susceptible individuals. Women who are pregnant must not take Lynkuet. Careful individual evaluation is required before prescribing.

How Veozah and Lynkuet Fit Into the Root-Cause Approach at Aniron Functional Medicine and Integrative Psychiatry

Both medications target the neurological trigger of hot flashes directly and effectively. However, they do not address the underlying biological factors, insulin resistance, gut dysfunction, thyroid imbalance, nutritional deficiencies, cortisol dysregulation, or liver detoxification, that make symptoms more severe in the first place. They also do not provide the bone, cognitive, cardiovascular, or genitourinary protection that HRT offers.

At Aniron Functional Medicine and Integrative Psychiatry, these medications are valuable tools within a broader plan. For women who qualify and choose to use them, Veozah or Lynkuet can provide significant and rapid hot flash relief. Alongside that relief, the root-cause work continues, addressing gut health, nutrition, thyroid function, cortisol regulation, and inflammation to produce the most complete and lasting improvement possible.

Other Non-Hormonal Prescription Options

Beyond Veozah and Lynkuet, several other non-hormonal prescription medications carry clinical evidence for specific menopause symptoms. A review published in PMC confirmed that SSRIs and SNRIs produce meaningful reductions in hot flash frequency and carry evidence for mood and anxiety benefits during the menopausal transition. Gabapentin carries evidence for both vasomotor symptoms and sleep disruption. Clonidine may reduce hot flash frequency in some women. Wendy evaluates each patient’s full symptom picture, medical history, and medication interactions before recommending any prescription option.

What to Expect at Aniron Functional Medicine and Integrative Psychiatry

Every patient receives an individualized evaluation. No two menopause presentations are the same. The process begins with a comprehensive intake covering full medical history, current symptoms, past treatments, family history, and health goals. Comprehensive lab testing follows including thyroid panels, micronutrient levels, inflammatory markers, fasting insulin, MTHFR status, gut health evaluation, and adrenal function assessment.

From there, a personalized plan takes shape. That plan may include targeted supplementation, dietary guidance, lifestyle strategies, gut health protocols, prescription medications when appropriate, and integrative psychiatry support for mood and sleep. Follow-up visits track progress and adjust the plan as the patient’s clinical picture evolves. In-person appointments are available in Lehi and Bountiful. Telehealth appointments serve patients across Utah and Idaho.

Who This Approach Serves

This non-HRT, root-cause approach to menopause management serves women across a wide range of circumstances. It is particularly valuable for:

  • Women with hormone-sensitive cancers for whom HRT is contraindicated
  • Women with a history of blood clots, DVT, or pulmonary embolism
  • Women with endometriosis who prefer to avoid systemic estrogen
  • Women who do not tolerate HRT due to side effects
  • Women who prefer a non-hormonal approach as a personal choice
  • Women with significant gut, thyroid, adrenal, or metabolic dysfunction driving their symptoms
  • Women who want to address root causes rather than manage symptoms indefinitely
  • Women who want to combine non-HRT prescription support with comprehensive root-cause care

Lastly

Non-HRT menopause alternatives in Utah offer real, evidence-informed relief for women who cannot or choose not to use hormone therapy. At Aniron Functional Medicine and Integrative Psychiatry, Wendy Edwards, MSN, APRN, FNP-BC, PMHNP-BC addresses the root causes driving symptoms not just the symptoms themselves. Every patient receives a personalized plan built on comprehensive lab testing, clinical evidence, and individualized care. New FDA-approved options like Veozah and Lynkuet now give women who cannot use HRT powerful, targeted prescription tools for hot flash relief. Combined with root-cause functional medicine support, these options make comprehensive menopause care more accessible than ever. In-person appointments are available in Lehi and Bountiful. Telehealth serves patients across Utah and Idaho. Call Aniron Functional Medicine and Integrative Psychiatry today at (801) 889-2995.

Sources


Hickey, M., et al. (2017). Non-hormonal treatments for menopausal symptoms in women with breast cancer: Narrative review. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC6445536/

Gartoulla, P., et al. (2023). A review of hormone and non-hormonal therapy options for the treatment of menopause. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC10226543/

Iqbal, A. Z., et al. (2023). Effects of omega-3 polyunsaturated fatty acids intake on vasomotor symptoms, sleep quality and depression in postmenopausal women: A systematic review. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574492/

Freeman, M. P., et al. (2011). Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: A preliminary open trial. PubMed. https://pubmed.ncbi.nlm.nih.gov/21037490/

Minihane, A. M. (2025). Omega-3 fatty acids, brain health and the menopause. Therapeutic Advances in Psychopharmacology. https://journals.sagepub.com/doi/10.1177/20533691251341701

Ma, M. L., et al. (2022). Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis. Frontiers in Public Health. https://www.frontiersin.org/articles/10.3389/fpubh.2022.979649/full

Rao, A., et al. (2013). Relora reduces cortisol and improves mood in moderately stressed adults. Journal of the International Society of Sports Nutrition. https://jissn.biomedcentral.com/articles/10.1186/1550-2783-10-37

Hellhammer, J., et al. (2014). A soy-based phosphatidylserine/phosphatidic acid complex normalizes the stress reactivity of the HPA axis. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237891/

Bannai, M., & Kawai, N. (2015). The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC4397399/

Park, H., et al. (2011). A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer, 19(6), 859. https://pubmed.ncbi.nlm.nih.gov/19171696/

Mughal, Z. U. N., et al. (2025). FDA approves Veozah (fezolinetant) for menopausal symptoms: A new non-hormonal option. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401328/

Bayer. (2025). Bayer’s Lynkuet (elinzanetant), the first and only neurokinin 1 and neurokinin 3 receptor antagonist, receives FDA approval for moderate to severe hot flashes due to menopause. https://www.bayer.com/en/us/news-stories/lynkuet

Disclaimer
Results are not guaranteed. Individual results may vary. This content is for informational and educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement or treatment protocol, particularly if you have a history of cancer, blood clots, or other serious medical conditions.